The Cytotoxic T Lymphocyte Protein 4 pipeline drugs market research report outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cytotoxic T Lymphocyte Protein 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Genetic Disorders, and Non Malignant Disorders which include the indications Solid Tumor, Non-Small Cell Lung Cancer, Rheumatoid Arthritis, Autoimmune Disorders, Neurofibromatoses Type I (Von Recklinghausen’s Disease), and Inflammatory Myofibroblastic Tumor (IMT). It also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 targeted therapeutics development with respective active and dormant or discontinued products.
The Cytotoxic T Lymphocyte Protein 4 pipeline targets constitutes close to 83 molecules. Out of which, approximately 82 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 9, 18, 16, 3, 29, and 4 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Cytotoxic T Lymphocyte Protein 4 overview
CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. Inhibition of receptor acts as a major negative regulator of T-cell responses.
For a complete picture of Cytotoxic T Lymphocyte Protein 4’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
